Drug Trial Radar · NCT04934475
MInimal Residual Disease Adapted Strategy
Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
791
Actual
Start
Dec 8, 2021
Primary completion
Sep 30, 2024
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Intergroupe Francophone du MyelomeResearch network
- Sponsor type
- Research network
- Collaborators
- Amgen; Sanofi; Bristol-Myers Squibb
- First posted
- Jun 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 66 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates. Patients will be classified at diagnosis according to cytogenetics (standard vs high-risk cytogenetics defined by the LP score including 17p deletion, t(4;14), del(1p32), gain 1q, trisomy 21 and trisomy 5).
Conditions
- Multiple Myeloma
Interventions
IsatuximabDrug
Treatment with Isa-KRD during induction and consolidation , with Lenalidomide (Revlimid) or Iberdomide + Isatuximab during maintenance phase
ASCTProcedure
ASCT for ams B, C and D during consolidation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Negative MRD rateTime frame: Time Frame: change from post induction baseline MRD at end of consolidation phase (6 months)
- Negative MRD rateTime frame: change from post induction baseline MRD at 1 years
- Negative MRD rateTime frame: change from post induction baseline MRD at 2 years
- Negative MRD rateTime frame: change from post induction baseline MRD at 3 years
Locations
73 sites in 3 countries. Site status is shown where the registry gives one.
Institut Jules Bordet
Brussels, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Grand Hôpital de Charleroi - Site de Notre-Dame
Charleroi, Belgium
Hôpital Jolimont
Haine-Saint-Paul, Belgium
CHU de Liège
Liège, Belgium
CHU UCL Namur (Site Godinne)
Yvoir, Belgium
CHU Amiens Sud
Amiens, France
CHRU-Hôpital du Bocage
Angers, France
Centre Hospitalier d'Argenteuil Victor Dupouy
Argenteuil, France
Centre Hospitalier H.Duffaut
Avignon, France
Centre hospitalier de la Côte Basque
Bayonne, France
Hôpital Jean Minjoz
Besançon, France
Centre Hospitalier Simone Veil
Blois, France
Hôpital Avicenne
Bobigny, France
Polyclinique Bordeaux Nord Acquitaine
Bordeaux, France
CHRU Hôpital Haut Lévêque - Centre François Magendie
Bordeaux Pessac, France
Hôpital de Fleyriat
Bourg-en-Bresse, France
CHRU Brest - Hôpital A. Morvan
Brest, France
CHU Caen - Côte de Nacre
Caen, France
CH René Dubos
Cergy-Pontoise, France
Centre Hospitalier William Morey
Chalon-sur-Saône, France
CH Chambéry
Chambéry, France
Hôpital d'Instruction des Armées Percy
Clamart, France
Chu Estaing
Clermont-Ferrand, France
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, France
CHU Henri Mondor
Créteil, France
CHU Dijon Hôpital d'enfants
Dijon, France
Centre Hospitalier Général
Dunkirk, France
CHRU Hôpital A. Michallon
Grenoble, France
CHD Vendée
La Roche-sur-Yon, France
CHV André Mignot - Université de Versailles
Le Chesnay, France
CH de Chartres - Hôpital Louis Pasteur
Le Coudray, France
Hôpital Jacques Monod
Le Havre, France
Centre Hospitalier
Le Mans, France
CHRU Hôpital Claude Huriez
Lille, France
GH de l'Institut Catholique Saint Vincent
Lille, France
Centre Hospitalier Universitaire (CHU) de Limoges
Limoges, France
Hôpital du Scorff
Lorient, France
Centre Léon Bérard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.